Compare Natera Inc. Common Stock (NTRA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.49B). The key difference: Natera Inc. Common Stock is far larger — about 38.3× State Street SPDR S&P Homebuilders ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| NTRA | XHB | |
|---|---|---|
Market Cap | $57.03B | $1.49B |
Volume | 1,131,157 | 1,578,908 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $121.36 |
52-Week Low | $179.42 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.70, up 0.69% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. Recent news highlights mixed housing data, with rising mortgage rates pressuring the sector but new legislation and institutional interest offering potential support. The ETF lacks current fundamental ratio data but tracks homebuilder stocks sensitive to economic cycles.
The outlook for XHB hinges on housing market dynamics; opportunities exist if affordability improves or construction accelerates, but risks include persistent high rates and economic slowdowns. Investor sentiment is cautious amid volatile home sales data, requiring close watch on macroeconomic indicators for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
